<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228576</url>
  </required_header>
  <id_info>
    <org_study_id>TREVISE</org_study_id>
    <nct_id>NCT03228576</nct_id>
  </id_info>
  <brief_title>Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association</brief_title>
  <official_title>Observationnal Multicenter Study on a Prospective Cohort of Kidney Transplanted Patients Receiving a Year After Transplant an Extended Releasing Tacrolimus-Everolimus Association</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney
      transplant. It combined immunosupressive properties of both products and reduce the
      nephrotoxicity of tacrolimus by lowering the dosage.

      The commercialisation of a new extended release Tacrolimus pharmaceutical form and the lack
      of information justify a modality of use and tolerence evaluation of this new association,
      commonly used.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">April 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of the Certican®-Envarsus® association</measure>
    <time_frame>During 1 year, between each visit (J0, M3, M6, M9, M12)</time_frame>
    <description>Assess clinical and biological tolerance of the Certican®-Envarsus® association on kidney transplanted patient, one year after transplant : study of adverse events with biological results (biochimy, hematology).
Study of incidence of Treatment-Emergent Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients description</measure>
    <time_frame>1 year</time_frame>
    <description>Describe the profil of included patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical evolution</measure>
    <time_frame>1 year</time_frame>
    <description>Describe the patients clinical evolution after a one year follow up : adverse events, renal function (creatinine)...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Describe treatments and switch modalities : tolerability with adverse events, conversion value between Prograf® and Envarsus®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>1 year</time_frame>
    <description>Describe the evolution of renal function during follow up : creatinine value during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Rejections and survival rates</measure>
    <time_frame>1 year</time_frame>
    <description>Assess acute graft rejections (confirmed by a biopsy with the Banff classification and creatinine value) and transplants survival rates a year after the switch : all renal biopsies will be reported, with the reason for the biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>1 year</time_frame>
    <description>Assess medication compliance during the switch and by the end of the study, to evaluated by doctor by asking the patient and with pharmacological concentrations (used in nephrology)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Transplant</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>TREVISE</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Extended release Tacrolimus-Everolimus association</intervention_name>
    <description>Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus</description>
    <arm_group_label>TREVISE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 18 years old with kidney transplantation for at least one year.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old

          -  Patients informed and giving his agreement to the use of every collected data

          -  Patients with kidney transplantation for at least one year and being treated with the
             immunosppressive assiociation of Tacrolimus (Prograf ®)-Everolimus

          -  Patients whose investigators decides to switch from Prograf ® to an Envarsus
             ®-Everolimus association

        Exclusion Criteria:

          -  Other transplantation

          -  Drug or alcohol abuse

          -  Patients unable to understand the purpose or modalities of this study, unable to give
             his agreement or unable to stick to the protocol

          -  Patients on an interventionnal protocol when included
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine THIERRY</last_name>
    <phone>0549443415</phone>
    <email>antoine.thierry@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandy BERTIN</last_name>
    <phone>0549443227</phone>
    <email>sandy.bertin@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WESTEEL Pierre-François, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SAYEGH Johnny, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOUVIER Nicolas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HENG Anne-Elisabeth, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine THIERRY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GOLBIN Léonard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ETIENNE Isabelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAILLARD Sophie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BUCHLER Mathias, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Envarsus</keyword>
  <keyword>Everolimus</keyword>
  <keyword>kidney</keyword>
  <keyword>Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

